Curaleaf (OTCMKTS:CURLF) Trading Down 3.3% – Here’s What Happened

Curaleaf Holdings, Inc. (OTCMKTS:CURLF)’s share price traded down 3.3% during mid-day trading on Monday . The stock traded as low as $2.85 and last traded at $2.92. 367,347 shares traded hands during mid-day trading, a decline of 58% from the average session volume of 870,768 shares. The stock had previously closed at $3.0190.

Wall Street Analyst Weigh In

A number of research firms have recently commented on CURLF. ATB Capital upgraded shares of Curaleaf to an “outperform” rating in a report on Tuesday, December 2nd. Canaccord Genuity Group upgraded Curaleaf to a “strong-buy” rating in a research note on Thursday, October 9th. Atb Cap Markets raised Curaleaf from a “hold” rating to a “strong-buy” rating in a report on Tuesday, December 2nd. Finally, Alliance Global Partners reaffirmed a “buy” rating on shares of Curaleaf in a report on Monday. Two equities research analysts have rated the stock with a Strong Buy rating and two have issued a Buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Strong Buy”.

Curaleaf Price Performance

The company has a market capitalization of $1.94 billion, a P/E ratio of -8.92 and a beta of 0.77. The company has a debt-to-equity ratio of 0.96, a current ratio of 1.47 and a quick ratio of 0.71. The firm’s 50-day moving average is $2.76 and its 200-day moving average is $2.24.

Curaleaf (OTCMKTS:CURLF) last issued its quarterly earnings results on Wednesday, November 5th. The company reported ($0.06) earnings per share for the quarter, topping the consensus estimate of ($0.07) by $0.01. Curaleaf had a negative net margin of 19.50% and a negative return on equity of 15.57%. Analysts predict that Curaleaf Holdings, Inc. will post -0.25 EPS for the current fiscal year.

Curaleaf Company Profile

Curaleaf Holdings, Inc is a leading American cannabis company engaged in the cultivation, processing and distribution of both medical and adult-use cannabis products. Headquartered in Wakefield, Massachusetts, Curaleaf operates cultivation facilities, processing centers and retail dispensaries across multiple U.S. jurisdictions. The company’s vertically integrated model allows it to manage the entirety of its supply chain, from seed to sale, ensuring consistent quality and compliance with stringent regulatory requirements.

Curaleaf’s product portfolio spans a wide range of formats, including premium flower, vaporizer cartridges, edibles, tinctures, topicals and concentrates.